Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera

Ji Qiu, Gina Choi, Lin Li, Hong Wang, Sharon J. Pitteri, Sandra R. Pereira-Faca, Alexei L. Krasnoselsky, Timothy W. Randolph, Gilbert S. Omenn, Cim Edelstein, Matt J. Barnett, Mark D. Thornquist, Gary E. Goodman, Dean E. Brenner, Ziding Feng, Samir M. Hanash

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Purpose: We have implemented a high throughput platform for quantitative analysis of serum autoantibodies, which we have applied to lung cancer for discovery of novel antigens and for validation in prediagnostic sera of autoantibodies to antigens previously defined based on analysis of sera collected at the time of diagnosis. Materials and Methods: Proteins from human lung adenocarcinoma cell line A549 lysates were subjected to extensive fractionation. The resulting 1,824 fractions were spotted in duplicate on nitrocellulose-coated slides. The microarrays produced were used in a blinded validation study to determine whether annexin I, PGP9.5, and 14-3-3 theta antigens previously found to be targets of autoantibodies in newly diagnosed patients with lung cancer are associated with autoantibodies in sera collected at the presymptomatic stage and to determine whether additional antigens may be identified in prediagnostic sera. Individual sera collected from 85 patients within 1 year before a diagnosis of lung cancer and 85 matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were hybridized to individual microarrays. Results: We present evidence for the occurrence in lung cancer sera of autoantibodies to annexin I, 14-3-3 theta, and a novel lung cancer antigen, LAMR1, which precede onset of symptoms and diagnosis. Conclusion: Our findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens.

Original languageEnglish (US)
Pages (from-to)5060-5066
Number of pages7
JournalJournal of Clinical Oncology
Volume26
Issue number31
DOIs
StatePublished - Nov 1 2008
Externally publishedYes

Fingerprint

Annexin A1
Autoantibodies
Lung Neoplasms
Antigens
Serum
Collodion
Validation Studies
Carotenoids
Vitamin A

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Qiu, J., Choi, G., Li, L., Wang, H., Pitteri, S. J., Pereira-Faca, S. R., ... Hanash, S. M. (2008). Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. Journal of Clinical Oncology, 26(31), 5060-5066. https://doi.org/10.1200/JCO.2008.16.2388

Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. / Qiu, Ji; Choi, Gina; Li, Lin; Wang, Hong; Pitteri, Sharon J.; Pereira-Faca, Sandra R.; Krasnoselsky, Alexei L.; Randolph, Timothy W.; Omenn, Gilbert S.; Edelstein, Cim; Barnett, Matt J.; Thornquist, Mark D.; Goodman, Gary E.; Brenner, Dean E.; Feng, Ziding; Hanash, Samir M.

In: Journal of Clinical Oncology, Vol. 26, No. 31, 01.11.2008, p. 5060-5066.

Research output: Contribution to journalArticle

Qiu, J, Choi, G, Li, L, Wang, H, Pitteri, SJ, Pereira-Faca, SR, Krasnoselsky, AL, Randolph, TW, Omenn, GS, Edelstein, C, Barnett, MJ, Thornquist, MD, Goodman, GE, Brenner, DE, Feng, Z & Hanash, SM 2008, 'Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera', Journal of Clinical Oncology, vol. 26, no. 31, pp. 5060-5066. https://doi.org/10.1200/JCO.2008.16.2388
Qiu, Ji ; Choi, Gina ; Li, Lin ; Wang, Hong ; Pitteri, Sharon J. ; Pereira-Faca, Sandra R. ; Krasnoselsky, Alexei L. ; Randolph, Timothy W. ; Omenn, Gilbert S. ; Edelstein, Cim ; Barnett, Matt J. ; Thornquist, Mark D. ; Goodman, Gary E. ; Brenner, Dean E. ; Feng, Ziding ; Hanash, Samir M. / Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 31. pp. 5060-5066.
@article{d68e08f18c724e78b80eb41e97d65b2c,
title = "Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera",
abstract = "Purpose: We have implemented a high throughput platform for quantitative analysis of serum autoantibodies, which we have applied to lung cancer for discovery of novel antigens and for validation in prediagnostic sera of autoantibodies to antigens previously defined based on analysis of sera collected at the time of diagnosis. Materials and Methods: Proteins from human lung adenocarcinoma cell line A549 lysates were subjected to extensive fractionation. The resulting 1,824 fractions were spotted in duplicate on nitrocellulose-coated slides. The microarrays produced were used in a blinded validation study to determine whether annexin I, PGP9.5, and 14-3-3 theta antigens previously found to be targets of autoantibodies in newly diagnosed patients with lung cancer are associated with autoantibodies in sera collected at the presymptomatic stage and to determine whether additional antigens may be identified in prediagnostic sera. Individual sera collected from 85 patients within 1 year before a diagnosis of lung cancer and 85 matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were hybridized to individual microarrays. Results: We present evidence for the occurrence in lung cancer sera of autoantibodies to annexin I, 14-3-3 theta, and a novel lung cancer antigen, LAMR1, which precede onset of symptoms and diagnosis. Conclusion: Our findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens.",
author = "Ji Qiu and Gina Choi and Lin Li and Hong Wang and Pitteri, {Sharon J.} and Pereira-Faca, {Sandra R.} and Krasnoselsky, {Alexei L.} and Randolph, {Timothy W.} and Omenn, {Gilbert S.} and Cim Edelstein and Barnett, {Matt J.} and Thornquist, {Mark D.} and Goodman, {Gary E.} and Brenner, {Dean E.} and Ziding Feng and Hanash, {Samir M.}",
year = "2008",
month = "11",
day = "1",
doi = "10.1200/JCO.2008.16.2388",
language = "English (US)",
volume = "26",
pages = "5060--5066",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "31",

}

TY - JOUR

T1 - Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera

AU - Qiu, Ji

AU - Choi, Gina

AU - Li, Lin

AU - Wang, Hong

AU - Pitteri, Sharon J.

AU - Pereira-Faca, Sandra R.

AU - Krasnoselsky, Alexei L.

AU - Randolph, Timothy W.

AU - Omenn, Gilbert S.

AU - Edelstein, Cim

AU - Barnett, Matt J.

AU - Thornquist, Mark D.

AU - Goodman, Gary E.

AU - Brenner, Dean E.

AU - Feng, Ziding

AU - Hanash, Samir M.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Purpose: We have implemented a high throughput platform for quantitative analysis of serum autoantibodies, which we have applied to lung cancer for discovery of novel antigens and for validation in prediagnostic sera of autoantibodies to antigens previously defined based on analysis of sera collected at the time of diagnosis. Materials and Methods: Proteins from human lung adenocarcinoma cell line A549 lysates were subjected to extensive fractionation. The resulting 1,824 fractions were spotted in duplicate on nitrocellulose-coated slides. The microarrays produced were used in a blinded validation study to determine whether annexin I, PGP9.5, and 14-3-3 theta antigens previously found to be targets of autoantibodies in newly diagnosed patients with lung cancer are associated with autoantibodies in sera collected at the presymptomatic stage and to determine whether additional antigens may be identified in prediagnostic sera. Individual sera collected from 85 patients within 1 year before a diagnosis of lung cancer and 85 matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were hybridized to individual microarrays. Results: We present evidence for the occurrence in lung cancer sera of autoantibodies to annexin I, 14-3-3 theta, and a novel lung cancer antigen, LAMR1, which precede onset of symptoms and diagnosis. Conclusion: Our findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens.

AB - Purpose: We have implemented a high throughput platform for quantitative analysis of serum autoantibodies, which we have applied to lung cancer for discovery of novel antigens and for validation in prediagnostic sera of autoantibodies to antigens previously defined based on analysis of sera collected at the time of diagnosis. Materials and Methods: Proteins from human lung adenocarcinoma cell line A549 lysates were subjected to extensive fractionation. The resulting 1,824 fractions were spotted in duplicate on nitrocellulose-coated slides. The microarrays produced were used in a blinded validation study to determine whether annexin I, PGP9.5, and 14-3-3 theta antigens previously found to be targets of autoantibodies in newly diagnosed patients with lung cancer are associated with autoantibodies in sera collected at the presymptomatic stage and to determine whether additional antigens may be identified in prediagnostic sera. Individual sera collected from 85 patients within 1 year before a diagnosis of lung cancer and 85 matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were hybridized to individual microarrays. Results: We present evidence for the occurrence in lung cancer sera of autoantibodies to annexin I, 14-3-3 theta, and a novel lung cancer antigen, LAMR1, which precede onset of symptoms and diagnosis. Conclusion: Our findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens.

UR - http://www.scopus.com/inward/record.url?scp=55549117480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55549117480&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.16.2388

DO - 10.1200/JCO.2008.16.2388

M3 - Article

C2 - 18794547

AN - SCOPUS:55549117480

VL - 26

SP - 5060

EP - 5066

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 31

ER -